Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

In Response to Tuesday’s Oil Spill, Governor Jerry Brown
Ruptured Oil Pipeline Leads to 21,000 gallons of Oil Flowing into California Coa
Janet Yellen Awarded her Second Yale Degree
Japan’s Improved First-Quarter GDP Portrays a Recovering Economy
A Plane of Hawaiian Airlines Bound for Honolulu Made Emergency Landing in LAX af
U.S Supreme Court Ruling Says Employers Must Monitor Fees for 401(k) Accounts
Starbucks to Partner with Stopify for Music Streaming Services
Kering Sues Alibaba in the U.S Court for Selling Counterfeit Goods
Factory Activities and Consumer Confidence both have a Downturn Darkening US Eco
Nordstrom, Inc’s Lower than Expected Earnings Should not be a Reason to Worry
The Week Ended with a Gain for Oil In spite of Abundant supply
CFPB Aims to Improve Sloppy Services of Student-loan Servicers